Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer.

Autor:	Gupta G; Department of Microbiology and Molecular Cell Biology, Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, USA., Lee CD; Department of Microbiology and Molecular Cell Biology, Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, USA., Guye ML; Sentara Surgery Specialists, Sentara CarePlex Hospital, USA.; Sentara Cancer Network, Sentara Hospital Systems, USA., Van Sciver RE; Department of Microbiology and Molecular Cell Biology, Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, USA., Lee MP; Department of Microbiology and Molecular Cell Biology, Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, USA., Lafever AC; Department of Microbiology and Molecular Cell Biology, Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, USA., Pang A; Department of Microbiology and Molecular Cell Biology, Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, USA., Tang-Tan AM; Department of Molecular and Cell Biology, University of California, USA., Winston JS; Department of Pathology, Pathology Sciences Medical Group, Sentara Norfolk General Hospital, USA., Samli B; Department of Pathology, Pathology Sciences Medical Group, Sentara Norfolk General Hospital, USA., Jansen RJ; Department of Public Health, North Dakota State University, USA., Hoefer RA; Sentara Cancer Network, Sentara Hospital Systems, USA.; Dorothy G. Hoefer Foundation, Sentara CarePlex Hospital, USA., Tang AH; Department of Microbiology and Molecular Cell Biology, Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, USA.
Jazyk:	angličtina
Zdroj:	Annals of breast cancer and therapy [Ann Breast Cancer Ther] 2020 May 02; Vol. 4 (1), pp. 48-57.
DOI:	10.36959/739/525
Abstrakt:	Chemo-resistant breast cancer is a major barrier to curative treatment for a significant number of women with breast cancer. Neoadjuvant chemotherapy (NACT) is standard first- line treatment for most women diagnosed with high-risk TNBC, HER2+, and locally advanced ER+ breast cancer. Current clinical prognostic tools evaluate four clinicopathological factors: Tumor size, LN status, pathological stage, and tumor molecular subtype. However, many similarly treated patients with identical residual cancer burden (RCB) following NACT experience distinctly different tumor relapse rates, clinical outcomes and survival. This problem is particularly apparent for incomplete responders with a high-risk RCB classification following NACT. Therefore, there is a pressing need to identify new prognostic and predictive biomarkers, and develop novel curative therapies to augment current standard of care (SOC) treatment regimens to save more lives. Here, we will discuss these unmet needs and clinical challenges that stand in the way of precision medicine and personalized cancer therapy. Competing Interests: Conflict of Interest The authors describe no conflict of interests.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu